Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit
Plaintiff Lawyers: Ranbaxy ‘Facing Liabilities In The Billions’
Executive Summary
A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.